ScripA $1.3bn deal between Biogen, Inc. and Capsigen Inc. points to how a growing number of large biopharma companies are turning to small firms focused on developing novel capsid technology to aid their
ScripScrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. ICON Offers 30% Premium For PRA Health
ScripThe biopharma industry has high ambitions to improve therapies for patients across many disease categories, drawing on a wealth of technological advances that have been emerging and maturing in recent